JPRN-jRCT2031210640已完成未知
Agrylin Capsules 0.5 mg Drug Use-Result Survey
Contact for Clinical Trial Information0 个研究点目标入组 1,826 人开始时间: 2022年3月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 1,826
研究概览
简要总结
Incidence and number, seriousness, and outcomes of adverse reactions, and factors which might influence their occurrence were investigated concerning the safety specification in the RMP for Agrylin and important items for investigation in this survey, but no noticeable trends were seen.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All cases who received treatment with anagrelide hydrochloride.
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Agrylin Drug Use-Result SurveyEssential Thrombocythemia (ET)NCT03625895Takeda1,826
已完成
不适用
Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"Parkinson's DiseaseNCT03727139Takeda1,021
已完成
不适用
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary ConditionsNeurodegenerative DiseasesOsteoarthritisAutoimmune DiseasesCardiomyopathiesErectile DysfunctionEmphysemaNCT01953523Elliot Lander3,000
已完成
4 期
Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety DisorderGeneralized Anxiety DisorderNCT00624780Pfizer's Upjohn has merged with Mylan to form Viatris Inc.615
已完成
不适用
Drug Use Investigation for IMIGRAN TabletMigraine DisordersNCT01376141GlaxoSmithKline3,571